Cleared Traditional

K875161 - MAT (TM) MICROALBUMIN TEST

K875161 is the FDA 510(k) clearance for MAT (TM) MICROALBUMIN TEST by Wampole Laboratories. It is a Class 2 Immunology device (product code DCF) cleared through the Traditional 510(k) pathway after a 64-day FDA review.

K875161 · Wampole Laboratories · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Feb 1988
Decision
64d
Days
Class 2
Risk

K875161 is an FDA 510(k) clearance for the MAT (TM) MICROALBUMIN TEST. Classified as Albumin, Antigen, Antiserum, Control (product code DCF), Class II - Special Controls.

Submitted by Wampole Laboratories (Cranbury, US). The FDA issued a Cleared decision on February 17, 1988 after a review of 64 days - a notably fast clearance cycle.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5040 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Wampole Laboratories devices

Submission Details

510(k) Number K875161 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received December 15, 1987
Decision Date February 17, 1988
Days to Decision 64 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
40d faster than avg
Panel avg: 104d · This submission: 64d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code DCF Albumin, Antigen, Antiserum, Control
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5040
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - DCF Albumin, Antigen, Antiserum, Control

All 28
Devices cleared under the same product code (DCF) and FDA review panel - the closest regulatory comparables to K875161.
QM300 ALBUMIN ANTIBODY PACK
K882082 · Kallestad Diag, A Div. of Erbamont, Inc. · Jul 1988
QM300 CALIBRATOR D PACK
K881127 · Kallestad Diag, A Div. of Erbamont, Inc. · Apr 1988
QM300 ALBUMIN ANTIBODY PACK
K881126 · Kallestad Diag, A Div. of Erbamont, Inc. · Apr 1988
ALBUMIN IN SERUM
K873862 · Unipath , Ltd. · Oct 1987
ALBUMIN IN URINE
K873861 · Unipath , Ltd. · Oct 1987
IMMUNOGL. FRCT. OF RABBIT ANTISER.-ALBUM
K812496 · Dako Corp. · Sep 1981